Cargando…
Neurocysticercosis: Current Perspectives on Diagnosis and Management
Porcine cysticercosis, human taeniasis, and (neuro)cysticercosis are endemic in many low- and middle-income countries (LMIC) where they present a significant health burden to affected communities. Neurocysticercosis (NCC) is one of the leading causes of human epilepsy in many hyperendemic regions in...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8141574/ https://www.ncbi.nlm.nih.gov/pubmed/34041288 http://dx.doi.org/10.3389/fvets.2021.615703 |
_version_ | 1783696390194462720 |
---|---|
author | Butala, Caitlin Brook, T. M. Majekodunmi, Ayodele O. Welburn, Susan Christina |
author_facet | Butala, Caitlin Brook, T. M. Majekodunmi, Ayodele O. Welburn, Susan Christina |
author_sort | Butala, Caitlin |
collection | PubMed |
description | Porcine cysticercosis, human taeniasis, and (neuro)cysticercosis are endemic in many low- and middle-income countries (LMIC) where they present a significant health burden to affected communities. Neurocysticercosis (NCC) is one of the leading causes of human epilepsy in many hyperendemic regions in Latin America, Asia, and sub-Saharan Africa. The World Health Organization (WHO) reports an estimated 2.5–8.3 million cases of NCC annually with a disability-adjusted life year (DALY) burden of 2.8 million, but as for all neglected tropical diseases (NTDs), these values are likely to be underestimated. Diagnosis of NCC is complex and most accurately diagnosed using clinical neuroimaging that is unavailable in most hyperendemic regions in LMIC. On January 28, 2021, WHO will launch its road map for the NTDs' “Ending the neglect to attain the Sustainable Development Goals: a road map for neglected tropical diseases 2021–2030.” Taeniasis/cysticercosis is targeted for control success considered as steady increase in the number of countries with intensified control in hyperendemic areas [increasing from 2 (3%) in 2020 to 4 (6%) in 2023, to 9 (14%) by 2025, and to 17 (27%) by 2030]. Cross-cutting targets that include 100% access to at least basic water supply, sanitation, and hygiene in areas endemic for NTDs and 75% integrated treatment coverage for preventative chemotherapy will additionally impact on the taeniasis/cysticercosis/NCC complex. With no vaccine available for humans, prevention of infection depends on communication to the public of the life cycle of a complex zoonosis to promote behavior change, underpinned by practical control measures including treatment of human taeniasis and (neuro)cysticercosis with albendazole and praziquantel [widely used as part of the mass drug administration (MDA) deworming programs], surgery where appropriate, and effective vaccination and deworming for pigs supported by meat inspection. Here, we review recent advances in tools and implementation for Taenia solium taeniasis/(neuro)cysticercosis (TSTC) control and milestones on the onward path to elimination. |
format | Online Article Text |
id | pubmed-8141574 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-81415742021-05-25 Neurocysticercosis: Current Perspectives on Diagnosis and Management Butala, Caitlin Brook, T. M. Majekodunmi, Ayodele O. Welburn, Susan Christina Front Vet Sci Veterinary Science Porcine cysticercosis, human taeniasis, and (neuro)cysticercosis are endemic in many low- and middle-income countries (LMIC) where they present a significant health burden to affected communities. Neurocysticercosis (NCC) is one of the leading causes of human epilepsy in many hyperendemic regions in Latin America, Asia, and sub-Saharan Africa. The World Health Organization (WHO) reports an estimated 2.5–8.3 million cases of NCC annually with a disability-adjusted life year (DALY) burden of 2.8 million, but as for all neglected tropical diseases (NTDs), these values are likely to be underestimated. Diagnosis of NCC is complex and most accurately diagnosed using clinical neuroimaging that is unavailable in most hyperendemic regions in LMIC. On January 28, 2021, WHO will launch its road map for the NTDs' “Ending the neglect to attain the Sustainable Development Goals: a road map for neglected tropical diseases 2021–2030.” Taeniasis/cysticercosis is targeted for control success considered as steady increase in the number of countries with intensified control in hyperendemic areas [increasing from 2 (3%) in 2020 to 4 (6%) in 2023, to 9 (14%) by 2025, and to 17 (27%) by 2030]. Cross-cutting targets that include 100% access to at least basic water supply, sanitation, and hygiene in areas endemic for NTDs and 75% integrated treatment coverage for preventative chemotherapy will additionally impact on the taeniasis/cysticercosis/NCC complex. With no vaccine available for humans, prevention of infection depends on communication to the public of the life cycle of a complex zoonosis to promote behavior change, underpinned by practical control measures including treatment of human taeniasis and (neuro)cysticercosis with albendazole and praziquantel [widely used as part of the mass drug administration (MDA) deworming programs], surgery where appropriate, and effective vaccination and deworming for pigs supported by meat inspection. Here, we review recent advances in tools and implementation for Taenia solium taeniasis/(neuro)cysticercosis (TSTC) control and milestones on the onward path to elimination. Frontiers Media S.A. 2021-05-10 /pmc/articles/PMC8141574/ /pubmed/34041288 http://dx.doi.org/10.3389/fvets.2021.615703 Text en Copyright © 2021 Butala, Brook, Majekodunmi and Welburn. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Veterinary Science Butala, Caitlin Brook, T. M. Majekodunmi, Ayodele O. Welburn, Susan Christina Neurocysticercosis: Current Perspectives on Diagnosis and Management |
title | Neurocysticercosis: Current Perspectives on Diagnosis and Management |
title_full | Neurocysticercosis: Current Perspectives on Diagnosis and Management |
title_fullStr | Neurocysticercosis: Current Perspectives on Diagnosis and Management |
title_full_unstemmed | Neurocysticercosis: Current Perspectives on Diagnosis and Management |
title_short | Neurocysticercosis: Current Perspectives on Diagnosis and Management |
title_sort | neurocysticercosis: current perspectives on diagnosis and management |
topic | Veterinary Science |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8141574/ https://www.ncbi.nlm.nih.gov/pubmed/34041288 http://dx.doi.org/10.3389/fvets.2021.615703 |
work_keys_str_mv | AT butalacaitlin neurocysticercosiscurrentperspectivesondiagnosisandmanagement AT brooktm neurocysticercosiscurrentperspectivesondiagnosisandmanagement AT majekodunmiayodeleo neurocysticercosiscurrentperspectivesondiagnosisandmanagement AT welburnsusanchristina neurocysticercosiscurrentperspectivesondiagnosisandmanagement |